Tweet
<img alt="" height="1" width="1" />
BioSante cites positive GVAX study, shares rise
BusinessWeek
BioSante Pharmaceuticals said Thursday that its GVAX cancer treatment led to a reduction of cancer cells in leukemia patients who had been taking the cancer drug Gleevec for at least one year. In the study at the Johns Hopkins Kimmel Cancer Center, ...
BioSante rallies on study; drug stocks slipMarketWatch
BioSante cancer vax promising in small studyFierceVaccines
BioSante Announces Positive Data on Leukemia DrugOneMedPlace (blog)
TransWorldNews (press release) -Chicago Breaking Business - Tribune (blog) -Trading Markets (press release)
all 51 news articles »
More...